- Home
- PEPG vs COEP Comparison
PEPG vs COEP Comparison
Compare PEPG & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEPG
- COEP
- Stock Information
- Founded
- PEPG 2018
- COEP 2017
- Country
- PEPG United States
- COEP United States
- Employees
- PEPG N/A
- COEP 7
- Industry
- PEPG Biotechnology: Pharmaceutical Preparations
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PEPG Health Care
- COEP Health Care
- Exchange
- PEPG Nasdaq
- COEP Nasdaq
- Market Cap
- PEPG 43.2M
- COEP 49.1M
- IPO Year
- PEPG 2022
- COEP N/A
- Fundamental
- Price
- PEPG $1.29
- COEP $13.97
- Analyst Decision
- PEPG Buy
- COEP
- Analyst Count
- PEPG 3
- COEP 0
- Target Price
- PEPG $7.67
- COEP N/A
- AVG Volume (30 Days)
- PEPG 311.5K
- COEP 60.0K
- Earning Date
- PEPG 08-07-2025
- COEP 08-14-2025
- Dividend Yield
- PEPG N/A
- COEP N/A
- EPS Growth
- PEPG N/A
- COEP N/A
- EPS
- PEPG N/A
- COEP N/A
- Revenue
- PEPG N/A
- COEP $263,555.00
- Revenue This Year
- PEPG N/A
- COEP N/A
- Revenue Next Year
- PEPG N/A
- COEP N/A
- P/E Ratio
- PEPG N/A
- COEP N/A
- Revenue Growth
- PEPG N/A
- COEP N/A
- 52 Week Low
- PEPG $0.88
- COEP $2.31
- 52 Week High
- PEPG $10.15
- COEP $14.46
- Technical
- Relative Strength Index (RSI)
- PEPG 50.90
- COEP 71.92
- Support Level
- PEPG $1.37
- COEP $10.81
- Resistance Level
- PEPG $1.38
- COEP $11.62
- Average True Range (ATR)
- PEPG 0.13
- COEP 0.88
- MACD
- PEPG -0.01
- COEP 0.09
- Stochastic Oscillator
- PEPG 63.64
- COEP 88.62
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.